FDA Overrides Adcomm and Approves AZ's Oral SERD
28 Articles
28 Articles
AstraZeneca’s Etcamah Approved In US For ESR1-mutated Advanced Breast Cancer
The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.
AstraZeneca's drug Etcamah (camizestrant) in combination with a CDK4/6 inhibitor has been approved in the US as first-line treatment for advanced HR-positive breast cancer.
FDA approved the first hepsidine memetic to treat the true police.
The US Food and Drug Agency (FDA) approved a new medicine for breast cancer treatment developed by AstraZeneca Plc. The decision comes after an agency advisory committee voted against it, considering that it does not provide a "significant benefit" for patients. The medicine, known as the T-shirt and marketed under the Etcamah brand, received accelerated approval to be given in combination with other anti-cancer therapies, addressing patients wi…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
